CRISPR Therapeutics AG (CRSP) Presents at Citi's 18th Annual BioPharma Conference Transcript

CRISPR Therapeutics AG (NASDAQ:CRSP) Citi's 18th Annual BioPharma Conference Call September 6, 2023 11:20 AM ET

Company Participants

Sam Kulkarni - CEO

Conference Call Participants

Yigal Nochomovitz - Citigroup

Yigal Nochomovitz

We can get started. I'm Yigal Nochomovitz, I'm one of the biotech analysts at Citi. Next session is with the CEO of CRISPR, Sam Kulkarni. I cover CRISPR, I think, since the very beginning, since the IPO. So Sam, welcome. Thanks for doing this. Appreciate it.

Sam Kulkarni

Thanks for having us.

Question-and-Answer Session

Q - Yigal Nochomovitz

Year went by pretty fast. Here we are again. So I think a lot of people are familiar with the story, but I think it might be helpful if you just kind of frame the business case, frame the investment case. What's the near-term mission of the company? What's the grand vision for CRISPR?

Sam Kulkarni

Yeah. It's great to have this chat with you nearly eight years after IPO. And in fact, you know this since you covered us from the beginning, we're about 10 years as a company in October this year. It's hard to believe that time flies by this quickly. Everyone said, Gene editing is a new thing, and it's a new form of drug discovery first and then it's a new modality for drugs, and here we are on the cusp of what could be the first approved CRISPR-based medicine in the world with exa-cel later this year. Here we are having dosed over 200 patients across many different programs and platforms.

And I'm also proud of the fact that over time, we've built our own manufacturing facility, we have our own development engine. So we have a fully -- apart from the commercial piece of fully integrated biotech company and where we hope to take on not just few diseases